(Total Views: 696)
Posted On: 03/26/2024 9:39:03 PM
Post# of 148870
If LL is approved in oncology because it was studied with Keytruda then the indication, label and subsequent guidelines will likely reflect how it was studied- ie with Keytruda.
BUTT…Doctors potentially will have the ability to prescribe LL how they see fit- and that could be with other biosimilars. Or whatever other way they deem most appropriate for the patient. Hence, the Art of Medicine.
BUTT…Doctors potentially will have the ability to prescribe LL how they see fit- and that could be with other biosimilars. Or whatever other way they deem most appropriate for the patient. Hence, the Art of Medicine.
(12)
(0)Scroll down for more posts â–¼
